Daratumumab is making its way into earlier settings and is now an option for newly diagnosed multiple myeloma patients. A new clinical trial has just opened at five clinical trial sites comparing the four drug combination daratumumab, lenalidomide, bortezomib and dexamethasone vs. the three drug combo (lenalidomide, bortezomib, dex) alone.
Daratumumab was approved in November of 2015 for relapsed/refractory patients who had three prior therapies. Recently, it was granted fast-track approval to move the drug up for use in earlier care. Janssen has now submitted a request to the FDA for final approval to use daratumumab for patients receiving only one prior therapy if used with either Revlimid (lenalidomide) and dexamethasone OR Velcade (bortezomib) and dexamethasone. first relapse with with this combination of drugs for first relapse.
The trial will be open in St. Louis MO, Columbus, OH, Buffalo, NY, Boston, MA, and Chapel Hill, NC. SparkCures (see button below) has a myeloma clinical trial finder. They launched a new feature that provides the ability to sign up for notifications for trial sites that aren’t currently accepting patients. As soon as it begins accepting patients, SparkCures can either call or email you with updates. They are testing this out on a select few trials for now to see how useful it is. So please sign up to be notified and let us know if you like the feature – or with other suggestions on how they can help.
Learn more about this clinical trial here:Daratumumab Newly Diagnosed Clinical Trial